Introduction
Renal cell carcinoma (RCC) is a significant health problem in adults, accounting for more than 100,000 worldwide cancer-related deaths each year (1) , and is the most lethal of the common urological cancers (2) . Clearcell type compromises about 80% of RCCs. With the improvement of surgical techniques in radical and partial nephrectomy, the postoperative overall 5-year survival of patients with organ-confined disease has increased to 97.9% in stage T1aN0M0, 94.9% in stage T1bN0M0, and 88.4% in stage T2N0M0 (3) . Favorable prognosis relies on the acute early diagnosis of RCC (5-year survival rate-85%). Unfortunately, RCC often presents with few signs, symptoms, or laboratory abnormalities; thus, RCC is frequently only diagnosed at the advanced stage of the disease, when the prospects for a cure are dismal (a fiveyear survival rate of 9%) (4) . Early diagnosis of RCC is usually based on traditional manifestations such as pain, mass and hematuria, which are not always effective. Diagnosis and subsequent resection of the RCC are also not accurate because it only relies on the basis of imaging findings. The absence of biomarkers in early detection of RCC in clinical practices has complicated the early diagnosis and treatment of RCC. A non-invasive test in serum or urine will have a significant impact on patient management.
To date, many researchers have been dedicated to the identification of potential biomarkers for the early detection of RCC using different proteomebased techniques, including the newly emergent mass spectrometry method using isobaric tags for relative and absolute quantification (iTRAQ) (5, 6) . iTRAQ-based mass spectrometry, first introduced by Ross et al. (7) in 2004, is a technique of multiplexed protein quantitative mass spectrometry using amine-reactive isobaric tagging reagents. The advantage of iTRAQ is that it enables quantitation of multiple samples simultaneously but requires only a small amount of sample. It is utilized frequently in research of many other malignant diseases to investigate their unique proteomic profile (8) (9) (10) (11) (12) and thus provide a new method to explore the biomarkers in malignant tumors.
In this study, we used quantitative proteomic analysis by iTRAQ-based proteomic identification technology to identify proteins that are dysregulated in the serum and LC-MS of T1a clear-cell RCC (ccRCC) and healthy people. Bioinformatics analysis and crossplatform validation according to the Cancer Genome Atlas (TCGA) RCC database, which catalogs genetic mutations as well as the gene/microRNA expression/ regulation responsible for renal cancer, were also used in this study. To the best of our knowledge, this study is the first to highlight that T1a stage ccRCC accounts for 70-80% of all RCCs and always has a worse prognosis compared with other histological types of RCC (13) . Profiling of the differentially expressed serum proteins in the mentioned patient populations will help us to understand the etiology of ccRCC and even provide a new strategy for the early detection of ccRCC.
Materials and Methods

Study population and serum samples
The subjects included in this study were from the Department of Urology at Huashan Hospital, Fudan University from January 2010 to December 2015. A total number of 99 serum samples were obtained including 29 patients with ccRCC, 24 patients with a benign kidney mass, 28 patients with another type of urological tumor (20 cases of transitional cell carcinoma and 8 cases of prostate cancer or a male genital tumor), and 18 healthy controls. Patients with accompanying kidney diseases, cardiovascular disorders, or other cancers were excluded. All ccRCC patients had stage T1a cancer as confirmed by radiological evaluation and pathological assessment of the surgical specimens. Sera from each of these four groups of subjects were pooled and abbreviated as R for ccRCC, C for benign kidney masses, M for other urological tumors, and H for noncancer controls. The serum samples were preserved at -76°C before iTRAQ analysis. This study was approved by the Institutional Review Board of Huashan Hospital, Fudan University, China (#KY2011-026, version 01.2011.1.12 and #2011-017), and written consent was obtained from each participant before enrollment into this study. The clinical information and data were obtained from industrial or hospital records. The clinical characteristics of the subjects in this study are shown in Table S1 (http://biosciencetrends.com/docindex. php?year=2016&kanno=3).
iTRAQ labeling and nanoscale liquid chromatography coupled to tandem mass spectrometry (nano-LC-MS/MS)
For iTRAQ analysis, 200 μL of each serum sample was dissolved and digested in a trypsin buffer (2 μg of trypsin in 40 μL of dissolution buffer) in a 37°C water bath for 16-18 h, then centrifuged, collected, and quantified by optical density (OD) measurements at an absorbance of 280 nm. Based on the OD 280 values, an equivalent amount of peptide in each sample was subjected to iTRAQ labeling, according to the iTRAQ protocol (Applied Biosystems/MDS Sciex, Foster City, CA, USA). The samples were marked with iTRAQ tags as follows: iTRAQ117 for R, iTRAQ116 for C, iTRAQ115 for M, and iTRAQ114 for H. In order to obtain reliable results, the iTRAQ labeling experiment was replicated with the iTRAQ tags rearranged as follows: iTRAQ115 for R, iTRAQ117 for C, iTRAQ116 for M, and iTRAQ114 for H.
Next, the iTRAQ-labeled samples were pooled and fractionated by strong cation exchange chromatography on a polysulfoethyl 4.6 × 100 mm column (5 µm, 200 Å) (PolyLC Inc., Columbia, MD, USA) with a linear gradient of 0-500 mM KCl (10 mM KH 2 PO 4 , pH 3.0; 25% acetonitrile) over 75 min at a flow rate of 1 mL/ min. According to the chromatography results, the collected fractions were recombined into 10 fractions and then freeze-dried. After that, each of the freezedried fractions from the SCX column was redissolved in 100 μL of 0.1% formic acid aqueous solution and then desalted using Vydac C18 supermicro-centrifugation chromatography. The sample was then extracted and analyzed by nano-LC-MS/MS. The nano-LC-MS/MS was completed by a system composed of an AB SCIEX Triple Time-of-Flight (TOF) 5600 mass spectrometer (Concord, Canada) and a liquid chromatograph with a cHiPLC nanoflex chip driven by an Eksigent nanoUltra 2D Plus nano-LC (Dublin, CA, USA). Each sample was run through a sampling course and subsequent separation with tandem MS analysis. 
Gene Ontology (GO) analysis
The differentially expressed serum proteins in RCC were classified according to the GO category, including "biological process," "cell component," and "molecular function," respectively, by using the US National Institutes of Health (NIH) gene annotation software DAVID 6.7 (15) 
Results
iTRAQ-based mass spectrometry profiling of the differentially expressed serum proteins from ccRCC patients
In this study, we profiled differentially expressed serum proteins in 99 serum samples including 29 patients with stage T1a ccRCC, 24 patients with a benign renal mass, 28 patients with another type of urological tumor (18 for TCC), and 18 healthy controls using iTRAQ-based mass spectrometry. The basic clinical characteristics of subjects were collected as supporting information (Supplemental Data Table S1 , http://biosciencetrends. com/docindex.php?year=2016&kanno=3)
Overall, 263 serum proteins were identified after two runs of iTRAQ and validated the ratios of proteins from both runs by a scatter diagram with ratios in the first run on the x-axis and ratios in the replicated run on the y-axis ( Figure 1 ). The results from the two runs were consistent (Supplemental Data Table S2 , http://biosciencetrends. com/docindex.php?year=2016&kanno=3). Using cutoff values of 1.5-fold for overexpression and 0.67-fold for underexpression of a protein, 74 differentially expressed proteins were identified in ccRCC vs. healthy controls (Table 1) , with the identification of another 27 proteins (4 underexpressed and 23 overexpressed in ccRCC vs. the other three groups) according to the data from the TCGA database (Table 2 ; Figure 1 ). tandem MS was information-dependent acquisition (IDA). The resolving power of the screening performed by TOF MS was a full width at half maximum of 30,000, and the range was m/z 350-1250 in 250 ms. The top 30 abundant peptides with an ion peak greater than 120 counts/s and a range of charge from +2 to +5 were chosen to be analyzed by MS/MS with a range of m/z varying from 100 to 1800 in 100 ms for each TOF MS/MS screening time. The dynamic exclusion time was 18 s. When MS/MS was performed, the functions of enhanced iTRAQ splitting and auto-calculation of collision energy (AutoCE) were launched.
Calculation of the ratios of differentially expressed proteins
ProteinPilot (AB SCIEX, Framingham, MA, USA, 2012) software was then used to analyze the raw data. The signaling of the iTRAQ114 group served as the internal reference for the signal intensity, and all signals were normalized to it. The weighted average of the ratios of the respective peptides was calculated based on the protein quantitation results. False discovery rate analysis was conducted, and the detected protein threshold was set at less than 0.01. The proteomic database used in this study was the International Protein Index (IPI), Human v3.87. fasta (http://www.ebi.ac.uk/, Copyright © The European Bioinformatics Institute, 2013). Finally, the ratios of proteins of these four groups of samples with different iTRAQ tag labels were calculated as the averages of the ratios from two runs with different labeling sequences.
Integration and hierarchical clustering analysis of iTRAQ data against the TCGA database on RCC
The TCGA database catalogs genetic mutations as well as the gene/microRNA expression/regulation responsible for cancer risk and development using recently developed high-throughput genomic analysis techniques that were initiated in 2005. TCGA provides genomic characterization and sequence analysis of more than 20 different tumor types. In this study, the gene/ microRNA expression pattern and clinical information of more than 500 patients with kidney renal clear-cell carcinoma (KIRC) were downloaded from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/).
For cluster profiling, the median expression value of each protein across the samples was set to zero. Cluster 3.0 and Tree View software (http://rana.lbl.gov/ EisenSoftware.htm) were used for the cluster analysis and representation (14) . The hierarchical clustering was performed on both genes and samples. Using a tree algorithm, these differentially expressed proteins were organized based on similarities in the expression profile. This allowed us to visualize and select genes based on individual expression profiles.
Cross-platform analysis of the TCGA database vs. our differentially expressed proteins
To compare these 27 differentially expressed serum proteins, we downloaded the kidney tissue gene expression patterns from 31 normal controls and 205 patients with T1 ccRCC from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). We first analyzed the 27 gene expression patterns in the 30 normal controls and the 202 patients with T1 ccRCC, 1 normal control and 3 patients with T1a ccRCC (Figure 2A ). Hierarchical and heat map analyses of 27 gene expression patterns showed that 9 (C1qc, C1qb, Anxa1, Lyz, Cp, Agt, Zg16b, S100a8, And S100a9) were upregulated and 2 (Serpina4 And Lum) were downregulated in both serum and tissue samples (Table 1) . These 11 genes were selected for In this study, we first poured serum samples together from each of these four groups of subjects and performed the iTRAQ analyses two times. A total of 263 proteins after two iTRAQ runs were identified and validated, and the data were plotted on graphs. The x-axis indicates the value of the ratios in the first run, while the y-axis refers to those of the second run. Grouping of the differentially expressed proteins in this study. Note: R indicates patients with ccRCC, C indicates patients with a benign kidney mass; M indicates patients with another type of urological tumor; and H indicates noncancer controls. IPI00022394  IPI00643948  IPI00218918  IPI00019038  IPI00017601  IPI00032220  IPI00060800  IPI00007047  IPI00027462  IPI00328609  IPI00020986  IPI00022389  IPI00009866  IPI00290078  IPI00909059  IPI00022417  IPI00009867  IPI00022974  IPI00552768  IPI00021854  IPI00218407  IPI00743766  IPI00218732  IPI00953689  IPI00021841  IPI01025667  IPI00163207   Proteins  C1QC  C1QB  ANXA1   LYZ  CP  AGT  ZG16B  S100A8  S100A9  SERPINA4   LUM  CRP  KRT13  KRT4  KRT6A  LRG1  KRT5  PIP  TXN  APOA2  ALDOB  FETUB  PON1  AHSG  APOA1  SERPINA3 Figure 2B ).
Association of selected proteins with the tumor stage and grade in comparison to the TCGA database
Next, we selected 11 proteins from these 27 differentially expressed serum proteins for confirmation , Association of C1QC, C1QB, S100A8, S100A9, and LUM expression with the RCC stage. We selected these differentially expressed serum proteins for association with the RCC stage using data from the TCGA database including 31 normal controls and 205 patients with T1 RCC. (B), Association of C1QC, C1QB, CP, and LUM expression with the RCC grade. We selected these differentially expressed serum proteins for association with the RCC grade using data from the TCGA database including 31 normal controls and 205 patients with T1 RCC.
and association with the clinicopathological data from the TCGA database. Our data showed that the expression of C1QC, C1QB, S100A8, and S100A9 proteins was significantly increased in RCC and associated with an advanced stage of disease (p < 0.01; Figure 3A ; Supplemental Data Table S3 , http://biosciencetrends.com/docindex. php?year=2016&kanno=3). The expression of ceruplasmin (CP) was also significantly increased, whereas lumican (LUM) was significantly decreased in the RCC samples vs. the controls (p < 0.01; Figure 3B ; Supplemental Data Table S4 , http://biosciencetrends. We performed gene ontology analysis to group the functions of these differentially expressed serum proteins in ccRCC using data from the NIH DAVID database. 
com/docindex.php?year=2016&kanno=3).
Identification of the functions of these differentially expressed serum proteins in ccRCC
After that, we employed NIH DAVID 6.7 software (http://david.abcc.ncifcrf.gov/home.jsp) to assess the potential functional categories of these 27 differentially expressed serum proteins in early ccRCC. The cell component analysis in GO by NIH DAVID (Supplemental Data Figure S1 , http://biosciencetrends. com/docindex.php?year=2016&kanno=3) showed that S100A8, S100A9, LUM, ZG16B, C1QC, C1QB, SERPINA4, and CP proteins are secreted proteins and that LUM, LYZ, AGT, ZG16B, C1QB, CP, and SERPINA4 proteins are found in the extracellular region. Biological process analysis presented that most of these 11 genes are involved in the host defense response, inflammatory response, and the response to wounding, indicating that the identified proteomic expression pattern might reflect the early change in the serum microenvironment of ccRCC ( Figure 4) . As for the molecular functions of the differentially expressed serum proteins, they might be involved in four kinds of biological processes including enzyme inhibitor activity, structural molecule activity, identical protein binding, and lipid binding ( Figure 5 ).
Discussion
The treatment and prognosis of ccRCC largely depends on the tumor stage and the pre-existing conditions of the patients. In other words, surgery is still the best option for treating these patients, if diagnosed at an early stage. The lack of biomarkers to distinguish the malignant and benign lesions is the biggest challenge in ccRCC. Imaging has limited accuracy and might lead to unnecessarily surgery. Biopsy is a kind of accurate detection method for ccRCC but the invasive procedure and other side effects might limit its use. A non-invasive test such as urine or a blood-based test might provide a new idea for RCC diagnosis. In the current study, we performed proteomics analysis by using iTRAQ and several proteins have been identified as promising biomarkers for the accurate diagnosis of ccRCC although further investigation is still needed. In our study, we identified 27 differentially expressed serum proteins, 11 of which were cross-validated in RCC tissues against the TCGA database. Moreover, we found that expression of C1QC, C1QB, S100A8, S100A9, CP, and LUM proteins was associated with the RCC stage and/or grade. Of the dysexpressed proteins, 8 of them including S100A8, S100A9, LUM, ZG16B, C1QC, C1QB, SERPINA4, and CP proteins were secreted proteins and thus have the potential to be used as a serum biomarker in the diagnosis of ccRCC, especially in the early stage. iTRAQ technology, the proteomic technology that we chose to use in this study, has been utilized frequently for the assessment of differentially expressed proteins in many other diseases (8) (9) (10) (11) (12) , and previous publications have shown promising findings in the field of oncologic proteomic research. In RCC, to date, there have been two pioneering studies using the iTRAQ technique: one was related to the von Hippel-Lindau gene in RCC cells (5) , and the other one investigated gene profiling in RCC tissues at different stages (6) .
To the best of our knowledge, our current study is the first to highlight differentially expressed serum proteins from patients with stage T1a disease, since these patients are usually diagnosed during a health checkup. Moreover, we also utilized the IPI human proteomic database to identify certain differentially expressed proteins and the NIH DAVID database to functionally analyze these differentially expressed serum proteins. The TCGA KIRC database was used for cross-platform validation of the selected serum proteins at the relevant genetic level in a totally different population. Thus, we identified 27 differentially expressed serum proteins in ccRCC patients vs. healthy controls, those with benign renal masses, and those with another type of urological tumor. Four proteins were underexpressed and 23 were overexpressed. Hierarchical analysis showed that these 27 genes could constitute a proteomic expression pattern that is able to distinguish T1 ccRCC from normal controls. However, the regulation of these 27 proteins in the tissue samples was not exactly consistent with the levels of serum proteins measured by the iTRAQ test. This might be attributed to the possibility of posttranscriptional modifications and the inherited inaccuracy of this protein quantification. In addition, we found that the expression of the 11 differentially expressed serum proteins (C1QB, C1QC, ANXA1, LYZ, CP, ACT, ZG16B, S100A8, S100A9, SERPINA4, and LUM) was associated with the RCC tumor stage and grade. Functionally, C1QB and C1QC are complement subcomponent subunits (16) and are related to antibody-dependent and -independent immune responses in the human body (17) . They are able to induce apoptosis of prostate cancer cells by targeting the tumor suppressor WWOX and hampering cell adhesion via a mechanism which is still unknown (18) . As RCC has been demonstrated to be immunogenic, the association between C1q and the carcinoma is worthy of further study. Moreover, S100A8 and S100A9 are EF-hand Ca 2+ binding proteins. They are abundant in the cytosol of phagocytes and play a critical role in numerous cellular processes, such as motility and danger signaling, by interacting and modulating the activity of target proteins. The expression levels of S100A8 and S100A9 are increased in many types of cancer, including gastric, colon, pancreatic, bladder, ovarian, thyroid, breast, skin, and prostate cancers, but not in ccRCC according to previous studies (19) (20) (21) (22) (23) (24) . All four of these proteins are secreted proteins and are involved in the defense response, according to the GO analysis by NIH DAVID.
Our study suggested that ccRCCs might have 8 protein biomarkers that play important roles in the immune response, especially the defense response, although larger scale studies are needed to get more specific conclusions. The relationship between immune response including defense response and RCC needs further investigation and whether other defense response related proteins could also be biomarkers for early detection are also of great value. Dysregulated immune response is thought to be related to the rapid cell proliferation, metastasis and lower apoptosis of cancer cells.
Our findings are consistent with previous studies on functional analyses in ccRCC. The link between dysregulated immune response and ccRCC is not surprising. The reaction of the immune system plays a dual role in the development of carcinoma including ccRCC. The immune system could identify and control the proliferation of cancer cells to play the immunosurveilance function (25) . However, on the other hand, it could also promote chronic inflammation, immunoselection of defective immunogenic variants and even suppress antitumor immunity and thus provide a beneficial microenvironment for progression of carcinoma. Defective immune-editing to balance activation and inhibition is responsible for the occurrence, angiogenesis, metastasis, apoptosis and inhibition of malignant lesions including in ccRCC (26) .
Global analysis through protein analysis and pathway analysis may provide new significant applications in clinical practice. It might provide more than diagnostic markers. The pathway-derived metabolic products especially those proteins that are involved in the defense response might be predictive or even prognostic markers in patients and thus offer new methods for a deeper comprehension of malignant lesions (27) .
In conclusion, we identified several serum proteins that can distinguish ccRCC and other controls in serum. Most of them are involved in the biological defense response. If the promising proteins could be confirmed as dysregulated in the serum of ccRC patients that would suggest their potential as noninvasive biomarkers for early detection of RCC. The functional analysis of these proteins in RCC may lead to a novel mechanism of RCC development and progression, possibly revealing a novel strategy to treat RCC patients in the future.
